Literature DB >> 1517881

Sequential dermal microvascular and perivascular changes in the development of scleroderma.

R J Prescott1, A J Freemont, C J Jones, J Hoyland, P Fielding.   

Abstract

It has been previously proposed that there is a primary microvascular abnormality in patients with systemic sclerosis. In this study using conventional light and electron microscopy, immunohistochemistry, and labelled adenosine uptake techniques, changes in the dermal microvasculature have been related to the various clinical stages of skin disease in systemic sclerosis. The earliest pathological changes are seen in clinically normal skin. They constitute changes in endothelial cell function and their consequences. Perivascular oedema is an early feature. With progression in the clinical disease, there is, at first, an inflammatory cell infiltrate into the dermis, particularly the papillary and mid-dermis, and platelet aggregation within vessels. Further clinical progression is associated with increasing dermal fibrosis, loss of adnexae, and vascular effacement. It is postulated that the recruitment of different types of mononuclear cells into the dermis is causally linked with the preceding endothelial cell dysfunction and the subsequent induction of fibroblast proliferation and collagen synthesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517881     DOI: 10.1002/path.1711660307

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  102 in total

Review 1.  Bone marrow transplantation in the treatment of systemic sclerosis.

Authors:  F Viganego; R Nash; D E Furst
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 2.  Anti-endothelial cell antibodies in systemic sclerosis.

Authors:  Y Renaudineau; R Revelen; Y Levy; K Salojin; B Gilburg; Y Shoenfeld; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 3.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

4.  Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Authors:  G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

5.  Vascular leak is a central feature in the pathogenesis of systemic sclerosis.

Authors:  Tracy M Frech; Monica P Revelo; Stavros G Drakos; Maureen A Murtaugh; Boaz A Markewitz; Allen D Sawitzke; Dean Y Li
Journal:  J Rheumatol       Date:  2012-06-01       Impact factor: 4.666

6.  Systemic sclerosis and lupus: points in an interferon-mediated continuum.

Authors:  Shervin Assassi; Maureen D Mayes; Frank C Arnett; Pravitt Gourh; Sandeep K Agarwal; Terry A McNearney; Damien Chaussabel; Nancy Oommen; Michael Fischbach; Kairav R Shah; Julio Charles; Virginia Pascual; John D Reveille; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2010-02

Review 7.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

8.  Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma.

Authors:  R Sgonc; M S Gruschwitz; H Dietrich; H Recheis; M E Gershwin; G Wick
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

9.  Increased transendothelial migration of scleroderma lymphocytes.

Authors:  G H Stummvoll; M Aringer; J Grisar; C W Steiner; J S Smolen; R Knobler; W B Graninger
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

10.  Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers.

Authors:  C P Denton; X Shi-Wen; A Sutton; D J Abraham; C M Black; J D Pearson
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.